Dietary melatonin supplementation from mid-to late gestation increases umbilical artery blood flow and causes disproportionate fetal growth. Melatonin receptors have been described throughout the cardiovascular system; however, there is a paucity of data on the function of placental melatonin receptors. The objectives of the current experiment were to determine fetal descending aorta blood flow, umbilical artery blood flow, and placental and fetal development following a 4-wk uterine infusion of melatonin (MEL), melatonin receptor 1 and 2 antagonist (luzindole; LUZ), or vehicle (CON) from Day 62 to Day 90 of gestation. After 4 wk of infusion, umbilical artery blood flow and umbilical artery blood flow relative to placentome weight were increased (P , 0.05) in MEL-versus CON-and LUZ-infused dams. Fetal descending aorta blood flow was increased (P , 0.05) in MEL-versus CON-and LUZ-infused dams, while fetal descending aorta blood flow relative to fetal weight was increased in MEL-versus CON-infused dams and decreased in LUZ-versus CON-infused dams. Following the 4-wk infusion, we observed an increase in placental efficiency (fetal-placentome weight ratio) in MEL-versus LUZ-infused dams. The increase in umbilical artery blood flow due to chronic uterine melatonin infusion is potentiated by an increased fetal cardiac output through the descending aorta. Moreover, melatonin receptor antagonism decreased fetal descending aorta blood flow relative to fetal weight. Therefore, melatonin receptor activation may partially mediate the observed increase in fetal blood flow following dietary melatonin supplementation.
INTRODUCTION
Several animal models of fetal and placental growth restriction (e.g., maternal nutritional plane, maternal age, heat stress, hypoxic stress, and fetal number) have been developed to better unravel the relationship between uteroplacental blood flow, placental vascularity, and nutrient delivery to the fetus [1, 2] . In sheep, increasing uterine blood flow during the last half of gestation is vital for maintaining continual delivery of sufficient oxygen and nutrients to the exponentially growing fetus [3] [4] [5] . Maternal nutrient restriction causes aberrations in uterine blood flow and placental vascularity, which is highly associated with the magnitude of fetal growth restriction [4, 6] . Moreover, compromised pregnancies show a decrease in umbilical cord blood flow, which is due to a drop in umbilical blood flow velocity [7] . Consequently, low-birth-weight offspring from these compromised pregnancies have increased incidences of adult-onset diseases [8] , poor growth rates, and lower daily rates of gross energy accretion [9] . This association has prompted research in the development of therapeutics and/ or supplements to negate the consequences of intrauterine growth restriction during specific time points of gestation [5, 10] .
Melatonin supplementation has been associated with improved oxidative status and altered cardiovascular function [11] . Recently, our laboratory observed an increase in umbilical artery blood flow in ewes supplemented with dietary melatonin versus controls [6] . Therefore, melatonin supplementation may be used to negate the effects of intrauterine growth restriction during specific abnormalities in umbilical blood flow as long as sufficient uterine blood perfusion is maintained during pregnancy. Moreover, maternal melatonin supplementation caused disproportionate fetal growth at Day 130 of gestation, whereby fetal weight, ponderal index, and abdominal girth were increased in dams supplemented with melatonin versus adequate fed dams [6] . Supplementing melatonin may improve fetal development by increasing placental blood perfusion and/or uteroplacental nutrient transport capacity; however, a paucity of information exists on the mechanisms involved in these pathways. The alterations to umbilical cord blood flow following dietary melatonin supplementation may be mediated by 1) improved endothelial function via decreased vascular oxidative stress or 2) activation of cardiovascular melatonergic receptors 1 or 2, which have been shown to alter vascular reactivity depending on vessel origin [12, 13] . We hypothesized that chronic uterine infusion of melatonin receptor antagonist during midgestation would decrease feto-placental blood flow compared to that of vehicle (CON)-infused controls. The objectives were to examine umbilical artery blood flow, fetal descending aorta blood flow, and fetal and placental growth after surgically implanting mini osmotic infusion pumps containing melatonin (MEL) or melatonin receptor antagonist (luzindole; LUZ) on the gravid uterine horn.
MATERIALS AND METHODS

Animals
Animal care and use were according to protocols approved by the North Dakota State University Institutional Animal Care and Use Committee. Briefly, adult ewes were transported to the Animal Nutrition and Physiology Center (ANPC; Fargo, ND) in August of 2011 and fed to meet nutrient requirements during early gestation. Initially, 24 ewes were placed on pasture with ad libitum access to hay and water, with one ram of proven fertility fitted with a crayon marking harness. Evidence of mating was recorded every 12 h. At Day 28 of gestation, ewes were transported into a temperature-controlled facility (148C; ANPC) with a 12L:12D light cycle, with lights on at 0700 h and off at 1900 h for the remainder of the study. During Days 28-35 of pregnancy, ewes were placed in dorsal recumbency, and embryos were enumerated using B mode ultrasonography (Aloka SSD-3500; Aloka America, Wallingford, CT) with a 7.5-MHz, linear transrectal probe adapted from Schrick et al. [14] . Ewes carrying singleton pregnancies were stratified by weight, assigned to treatments, and housed in individual pens (0.91 3 1.2 m) at ANPC for the remainder of the experiment. On Day 35 of gestation, ewes were acclimated to a common alfalfa hay diet (2% of body weight) and provided trace-mineral salt blocks (4000 ppm Zn, 1600 ppm Fe, 1200 ppm Mn, 325 ppm Cu, 100 ppm I, 40 ppm Co; American Stockman, Overland Park, KS) and ad libitum access to water.
Surgeries
Melatonin was purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA), and luzindole (melatonin receptor 1 and 2 antagonist) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). One day prior to surgery, Alzet mini osmotic pumps (model 2ML4; Durect Corporation, Cupertino, CA) were prepared under a sterile hood using aseptic techniques. The 2ML4 model has a mean pumping rate of 2.80 ll/h (SD ¼ 0.14 ll/h), a mean fill volume of 2100 ll, and a pumping duration of 28 days (without catheter attachments). Because of the low solubility of melatonin and luzindole in water, solutions were prepared using a 45% dimethyl sulfoxide (DMSO) in water vehicle, which is compatible with the Alzet osmotic pumps as recommended by the manufacturer. Melatonin and luzindole were prepared at a concentration of 1 mg/ml in vehicle and then sterile filtered. In addition, vehicle alone (CON; 45% DMSO in water) was sterile filtered for control ewes. MEL, LUZ, or CON was loaded into a mini osmotic pump and then attached to a 20-cm PE-60 polyethylene catheter preloaded with the respective infusion treatment. The mini osmotic pump and catheter attachment were completely submerged in sterile, filtered saline and kept at 378C overnight (1 day prior to surgery).
Twenty-four hours prior to surgery ewes were removed from feed, and 12 h prior to surgery ewes were removed from water. On Day 62 of gestation, ewes were weighed and anesthetized with 3 mg/kg of body weight sodium pentobarbital. Anesthesia was maintained by intermittent infusion of sodium pentobarbital via a jugular catheter. The abdomen was sheared and cleaned with betadine scrub. Through a midline abdominal incision, the gravid uterine horn was exposed. During surgery, the uterus was covered with warm, sterile surgical towels, and liberal amounts of sterile saline (378C) were applied to the uterus every 5 min. During preliminary experiments, we catheterized the gravid uterine artery via a tertiary branch of the main gravid uterine artery. In these preliminary experiments, a tertiary branch of the main uterine artery was exposed via blunt dissection and isolated using surgical silk suture. The catheter was advanced retrograde, approximately 10 cm, toward the first bifurcation of the main uterine artery. This arterial catheter placement led to fetal death within the first 8 days postsurgery (treated, n ¼ 2; control, n ¼ 2). Therefore, surgeries were modified to allow placement of the catheter next to the gravid uterine vascular network of the mesometrial region. Fifteen ewes were selected for this modified surgical procedure, and all fetuses were viable during the 4-wk infusion period; however, one ewe was removed because of a twin pregnancy. Postsurgical care consisted of twice-daily i.m. injections of flunixin meglumine (50 mg/ml; Prevail, Meridian, ID) and once-daily i.m. injections of Penicillin G Procain (300 000 U/ml; Durvet, Blue Springs, MO) for the first 2 days postsurgery, following manufacturer recommendations. In addition, ewes were provided 50% of their dietary rations postsurgery, and feed was increased in a stepwise manner during this postoperative phase.
Color Doppler Ultrasonography
Umbilical artery and fetal descending aorta blood flow were assessed using a duplex B-mode (brightness mode) and D-mode (Doppler spectrum) program of the color Doppler SSD-3500 ultrasound instrument fitted with a 5.0-MHz finger transducer (UST-995; Aloka). Ultrasonography examinations started at 1300 h each day and lasted approximately 30 min for each ewe. For umbilical artery blood flow ultrasonography, evaluations took place on Days 50, 60, 70, 80, and 90 of gestation. Fetal descending aorta blood flow was evaluated on Days 60, 70, 80, and 90 of gestation. All dams were scanned transabdominally without the use of anesthesia. Briefly, for each ultrasonography examination dams were placed into an elevated crate, the abdomen was cleaned with soap and water, and sufficient Aquasonic transmission gel (Parker Laboratories, Fairfield, NJ) was applied to the probe. In B-mode a longitudinal section of the umbilical cord was visualized, and the pulsatile umbilical artery was confirmed by switching to a duplex screen containing B-mode imaging and Dopplerspectrum waveform plots. Previous data from our laboratory determined that umbilical artery blood flow via transabdominal imaging with Doppler ultrasonography could be recorded between Day 50 and Day 110 of gestation [6] . In addition, these measurements are optimal (based on previous umbilical and fetal imaging) between Day 60 and Day 90 of gestation. Therefore, treatments were applied during this optimal window of fetal and placental development. For the fetal descending aorta measurements, the fetal heart was visualized in the parasternal long-axis view to locate the aorta. The descending aorta blood-flow measurements were recorded in the lower thorax just above the diaphragm. Hemodynamic measurements for both vessels were obtained by placing the sample cursor over the vessel in B-mode while simultaneously recording pulsatile waves in D-mode. Three similar cardiac waveforms from each of two separate ultrasonography evaluations were obtained and averaged per ewe within 1 gestation day (at least six measurements per day). Cardiac cycle waveforms were plotted in D-mode by velocity (in cm/sec; y-axis) and time (sec; x-axis). Fetal heart rate (beats/min), pulsatility index (PI), resistance index (RI), and blood flow (BF) were calculated using preset functions on the ultrasound instrument. The average angle of insonation for the umbilical artery and fetal aorta measurements were 528 6 28 and 608 6 28, respectively. Abbreviations for equations are as follows: peak systolic velocity (PSV, cm/ sec), end diastolic velocity (EDV, cm/sec), mean velocity (MnV, cm/sec), and cross-sectional area of vessel (CSA, cm 2 ). Equations are as follows:
Blood Sampling
Maternal jugular vein blood samples were collected via venipuncture prior to ultrasonography examination on Days 60, 70, 80, and 90 of pregnancy. Umbilical cord blood (mix of arterial and venous blood) was collected on Day 90 following ewe euthanasia (see below for details). All blood samples were allowed to clot and were centrifuged at 2000 3 g for 15 min, and serum was collected and stored at À208C. Melatonin concentrations in serum were determined using an available melatonin ELISA kit (American Research Products, Belmont, MA) with an analytical sensitivity of 1.6 pg/ml and intraand interassay coefficients of variation of 9.1% and 9.4%, respectively. This assay was validated for use with sheep in our laboratory [6] . Total nitrites were determined using the QuantiChrom Nitric Oxide Assay Kit (BioAssay Systems, Hayward, CA). Briefly, following the manufacturer's recommendations, serum samples were deproteinized and quantified following the reduction of total nitrates to nitrites using the Griess method and analyzed against a linear nitrites standard curve (0-100 lM), with a sensitivity of 0.6 lM and intra-and interassay coefficients of variation of 3.5% and 4.6%, respectively.
Tissue Analysis
On Day 90 of gestation a blood sample was collected from all ewes, followed by the final ultrasonography examination. Ewes were weighed and euthanized via captive bolt followed by exsanguination. The uterus was removed at the cervix, and gravid uterine weight was recorded. Using a 10-ml syringe with an 18-gauge needle, chorioallantoic fluid and amniotic fluid were collected separately, centrifuged at 2000 3 g for 15 min, and stored at À208C. The gravid uterine horn was dissected, and the fetus was removed. The umbilicus was cut, and cord blood (10 ml) was collected, allowed to clot, centrifuged at 2000 3 g for 15 min, and stored at À208C. Fetal size measurements were recorded, and fetal organ weight and dimensions were recorded according to Lemley et al. [6] . Fetal ponderal index was calculated as fetal weight (kg)/crown rump length (m) 3 . At least three placentomes were removed from the uterus, and individual dimensions (length, width, and height) and weight were recorded prior to placentome separation. Approximately 5 grams of caruncle tissue and 5 grams of cotyledon tissue were snap frozen in supercooled isopentane (submerged in liquid nitrogen) and stored at À808C. In addition, the umbilical artery and fetal descending aorta were cleaned and snap frozen in supercooled isopentane (submerged in liquid nitrogen) and stored at À808C. Following tissue collection, the remaining placentomes were removed from the uterus, and individual placentome dimensions (length, width, and height) and weight were recorded. Total placentome weight, fetal membrane weight, and empty uterine weight was recorded. Each placentome was separated into caruncular and LEMLEY ET AL. cotyledonary portions and weighed. Placental efficiency was calculated as fetal weight/placentome weight. Day 90 blood flow measurments are reported as absolute flow and flow relative to fetal or placental weight.
Total tissue nitrites were determined in caruncle, cotyledon, umbilical artery, and fetal descending aorta tissue collected at Day 90 of gestation. These respective tissues were weighed and homogenized in PBS (pH 7.4) and centrifuged at 10 000 3 g for 10 min at 48C. Supernatants were collected, and total protein (mg) per tissue (g) was determined using a Coomassie Plus protein assay (Bradford assay; Thermo Scientific, Rockford, IL) following the manufacturer's protocol. Total tissue nitrites were determined using the QuantiChrom assay kit. Briefly, homogenized tissues were deproteinized following the manufacturer's recommendations, and samples were quantified following the reduction of total nitrates to nitrites using the Griess method and analyzed against a linear nitrite standard curve (0-100 lM), with a sensitivity of 0.6 lM and intra-and interassay coefficients of variation of 10.3% and 8.6%, respectively. Tissue nitrites are expressed as nanomole per milligram of placental protein.
Superoxide dismutase (SOD) activity was determined in caruncle and cotyledon tissue collected at Day 90 of gestation. Placental tissues were homogenized in cold PBS (pH 7.4) and centrifuged at 12 000 3 g for 5 min at 48C. Supernatants were collected, and total protein (mg) per tissue (g) was determined using a Coomassie Plus assay. Total SOD activity was determined using the EnzyChrom Superoxide Dismutase Assay Kit (BioAssay Systems) and analyzed against a quadratic SOD standard curve (0-3 U/ml), with a sensitivity of 0.05 U/ml and intra-and interassay coefficients of variation of 4.6% and 6.1%, respectively. Tissue SOD activity is expressed as milliunit per milligram of placental protein.
Melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2) expression were determined via commercially available ELISA kits from Cusabio Biotech Co., Ltd. (Wuhan, China). An ovine-specific MT1 ELISA kit was used to quantify MT1 protein concentrations relative to a standard curve. Briefly, 100 mg of caruncle or cotyledon tissue was rinsed with PBS, homogenized in 1 ml of PBS, and stored overnight at À208C. After two freeze-thaw cycles to break cell membranes, the cell lysates were centrifuged for 5 min at 5000 3 g at 48C. The supernatants were collected and assayed immediately. Even though the MT1 ELISA was specific to sheep, we analyzed nonspecific cross-reactivity by diluting supernatants from two separate ewes and determining MT1 concentrations, which were found to be parallel with the standard curve. The MT2 ELISA kit was specific to mouse; however, previous Western blot analysis in our laboratory revealed expression of MT2 in both the caruncle and cotyledon of Day 130 ovine placenta [15] . Similar to the ovine-specific MT1 ELISA, we validated the MT2 ELISA for nonspecific cross-reactivity by diluting supernatants from two separate ewes and determining MT2 concentrations, which were found to be parallel with the standard curve. Both melatonin receptor ELISA kits employed the quantitative sandwich enzyme immunoassay technique utilizing antibodies specific for MTNR1A (MT1) or MTNR1B (MT2) that were precoated onto the microplate. Standard and controls were included on each plate and quantified using biotin-avidin detection procedures. The MT1 ELISA detection range was 30-2000 pg/ml, with intra-and interassay coefficients of variation of 9.5% and 7.6%, respectively. The MT2 ELISA detection range was 0.1-10 ng/ml, with intraand interassay coefficients of variation of 7.9% and 8.1%, respectively. Melatonin receptor expression was expressed as picograms per milligrams of placental protein.
Statistical Analysis
Blood flow was determined in all 15 animals; however, one ewe was removed from the study prior to euthanasia due to a twin pregnancy. This resulted in the following experimental units for each treatment group: LUZ (n ¼ 5), CON (n ¼ 4), and MEL (n ¼ 5). Dependent variables measured over time were analyzed using repeated-measures ANOVA of the MIXED procedure of SAS (SAS version 9.2, SAS Institute Inc., Cary, NC), and means were separated using the PDIFF option of the LSMEANS statement. The model statement included infusion treatment, time, and their respective interaction. The effects of infusion treatment on dependent variables at Day 90 of gestation were tested with the MIXED procedure of SAS. The model statement included infusion treatment and fetal sex. Fetal sex was removed from the model statement if P . 0.25 was observed. For each treatment group, male and female fetuses were distributed as LUZ (n ¼ 3, n ¼ 2), CON (n ¼ 3, n ¼ 1), and MEL (n ¼ 3, n ¼ 2), respectively. Means were separated for infusion treatment using the PDIFF option of the LSMEANS statement. Least square means and SEM are reported. Statistical significance was declared at P 0.05.
RESULTS
Maternal and Fetal Melatonin Concentrations
In order to determine local delivery of hormone or hormone receptor antagonist to the feto-placental unit, melatonin concentrations were determined in both maternal and fetal serum (Fig. 1) . Daytime melatonin concentrations prior to surgery and infusion treatment (Day 60 of gestation) were similar across all treatment groups. On Days 70, 80, and 90 of gestation, MEL-treated dams had elevated (P , 0.05) peripheral concentrations of melatonin compared to those of CON-and LUZ-treated dams. Analysis of maternal concentrations of melatonin following surgery (Days 70, 80, and 90) revealed a main effect (P , 0.05) of infusion treatment whereby MEL ewes had a 25% increase in peripheral concentrations of melatonin compared to those of CON-and LUZ-treated dams (Fig. 1, left graph insert) . In addition, umbilical cord concentrations of melatonin at Day 90 of gestation were increased (P , 0.05) by 125% in fetuses from MEL-treated dams compared to CON-and LUZ-treated dams (Fig. 1, right graph insert) . In contrast, Day 90 melatonin concentrations in chorioallantoic fluid were not different (P ¼ 0.10) across treatment groups and averaged 19.3 6 2.2 pg/ml. Similarly, melatonin concentrations in Day 90 amniotic fluid were not different (P ¼ 0.65) across all treatment groups and averaged 14.7 6 2.1 pg/ml.
Fetal and Placental Hemodynamics
The interaction (P , 0.05) between infusion treatment and gestational day for umbilical artery blood flow is illustrated in MELATONIN AND FETO-PLACENTAL BLOOD FLOW decrease (P , 0.05) in umbilical artery blood flow compared to that of CON-and MEL-treated dams; however, this decrease in LUZ-treated dams as compared to CON-treated dams was no longer apparent on Day 90 of gestation. In addition, MELtreated dams showed an increase (P , 0.05) in umbilical artery blood flow on Day 90 of gestation compared to that of CONand LUZ-treated dams (Fig. 2) . Analysis of umbilical artery blood flow after the start of infusion treatments (Days 70, 80, and 90 of gestation) revealed a main effect of infusion treatment (P , 0.05) whereby LUZ-treated dams averaged lower umbilical artery blood flow compared to that of CONand MEL-treated dams (Fig. 2, graph insert) . Umbilical artery PI (Fig. 3A) and RI (Fig. 3B) were not different (P . 0.15) across treatment groups; however, a significant effect of gestation day was observed whereby umbilical artery PI decreased (P , 0.001) with increasing gestational age and umbilical artery RI increased (P , 0.05) with increasing gestational age.
The interaction (P , 0.05) between infusion treatment and gestational day for fetal descending aorta blood flow is illustrated in Figure 4 . Baseline fetal descending aorta blood flow at Day 60 of gestation was not different (P . 0.50) across all treatment groups. Infusion treatments commenced on Day 62 of gestation. On Day 70 of gestation, fetal descending aorta blood flow was not different (P . 0.25) across all treatment groups. On Day 80 of gestation, LUZ-treated dams had a discernible decrease (P , 0.05) in fetal descending aorta blood flow compared to that of CON-and MEL-treated dams; however, this decrease in LUZ-treated dams as compared to CON-treated dams was no longer apparent on Day 90 of gestation. In addition, MEL-treated dams showed an increase (P , 0.05) in fetal descending aorta blood flow on Day 90 of gestation compared to that of CON-and LUZ-treated dams (Fig. 4) . Analysis of fetal descending aorta blood flow after the start of infusion treatments (Days 70, 80, and 90 of gestation) revealed a main effect of infusion treatment (P , 0.05) whereby LUZ-treated dams averaged lower fetal descending aorta blood flow compared to that of CON-and MEL-treated dams (Fig. 4, graph insert) . Fetal descending aorta PI was not different (P . 0.80) across treatment groups; however, a significant effect (P , 0.05) of gestation day was observed whereby fetal aorta PI decreased with increasing gestational age (Fig. 5A) . Fetal descending aorta RI was not different (P . 0.20) across treatment groups or gestation day (Fig. 5B) . Fetal heart rate was not different (P . 0.30) across all treatment groups; however, a significant effect of gestation day was observed (P , 0.001) whereby fetal heart rate decreased with increasing gestational age (Fig. 5C) .
Maternal, Placental, and Fetal Growth
On Day 90 of gestation, ewe final body weight was not different (P . 0.80) across all treatment groups (Table 1 ). In addition, Day 90 gravid uterine weight and empty uterine weight were not different (P . 0.70) across all treatment groups (Table 1) . Fetal membranes, placentome number, placentome weight, and cotyledon weight were not different (P . 0.08) across all treatment groups. Caruncle weight at Day 90 of gestation was decreased (P , 0.05) in both LUZ-and MEL-treated dams compared to CON-treated dams (Table 1) . Average placentome weight and average placentome dimensions (length, width, and height) were not different (P . 0.30) across all treatment groups.
Fetal weight, fetal eviscerated weight, crown rump length, ponderal index, and biparietal distance at Day 90 of gestation LEMLEY ET AL.
were not different (P . 0.06) across all treatments (Table 2 ). In contrast, fetal abdominal girth was increased (P , 0.05) in MEL-treated dams compared to LUZ-infused dams, with CON-treated dams being intermediate (Table 2) . Absolute fetal organ mass and fetal organ mass relative to fetal weight are reported in Supplemental Table S1 (available online at www.biolreprod.org).
Placental efficiency (fetal-placental weight ratio) was increased (P , 0.05) in MEL-treated dams compared to LUZ-treated dams, with CON-treated dams being intermediate (Table 3) . Umbilical artery blood flow and umbilical artery blood flow relative to placental weight at Day 90 of gestation were increased (P , 0.05) in MEL-treated dams compared to CON-and LUZ-treated dams (Table 3) . Fetal descending aorta blood flow was increased (P , 0.05) in MEL-treated dams compared to CON-and LUZ-treated dams (Table 3) . Fetal descending aorta blood flow relative to fetal weight was decreased (P , 0.01) in LUZ-treated dams compared to CONtreated dams and increased (P , 0.01) in MEL-treated dams compared to CON-treated dams ( Table 3 ). The ratio of fetal aorta blood flow to umbilical artery blood flow was not different (P , 0.90) across all treatment groups (Table 3) .
Tissue Nitrites and SOD
Total serum nitrites in maternal peripheral circulation at Day 90 of gestation were not different (P , 0.50) across all treatment groups (Table 4) ; however, total serum nitrites from the umbilical cord were increased (P , 0.03) in both LUZ-and MEL-treated dams compared to CON-treated dams (Table 4) . Similarly, caruncular tissue concentrations of nitrites were increased in LUZ-and MEL-treated dams compared to CONtreated dams (Table 4) . Tissue concentrations of nitrites in the cotyledon, umbilical artery, and fetal descending aorta were not different (P . 0.10) across all treatment groups. Caruncular SOD activity was increased (P , 0.05) in MEL-treated dams compared to CON-and LUZ-treated dams (Table 4 ). In contrast, cotyledonary SOD activity was not different (P . 0.30) across all treatment groups (Table 4) . Placental MT1 and MT2 protein was not different (P ! 0.06) across all treatment groups.
DISCUSSION
Similar to our previous ovine dietary melatonin-supplementation model [6] , the results from the current study confirm an increase in umbilical artery blood flow following a chronic 4-wk infusion of melatonin during midgestation. Moreover, this increase in umbilical artery blood flow is potentiated by an MELATONIN AND FETO-PLACENTAL BLOOD FLOW increase in fetal cardiac output through the descending aorta. Earlier studies using radionuclide-labeled microsphere injections in sheep and goats have reported a large range in blood distribution (30%-60%) of total fetal cardiac output to the placenta [16] . In comparison, the current study reported a 40% distribution of blood from the fetal descending aorta to the umbilical artery. Therefore, Doppler ultrasonography may be a useful tool to repeatedly examine fetal blood distribution throughout mid-to late gestation in the same nonanesthetized animal, without the need for chronic catheterization and infusion of labeled microspheres. These Doppler ultrasonography techniques have been used extensively in human medicine for the prediction of fetal outcome [17] , while several vessels have been investigated in the human fetus, including the umbilical artery, descending thoracic aorta, middle cerebral artery, ductus venosus, inferior vena cava, and hepatic vein [18] . For the most part, both venous and arterial hemodynamics can serve as a good indicator of fetal compromise during late gestation [18] . In an overnourished, adolescent ewe model of intrauterine growth restriction, Carr et al. [19] recently described an increase in Doppler umbilical artery indices of resistance, which closely resembles the reduction in umbilical artery blood flow characterized using the Fick principle [20] . In the undernourished, adolescent ewe model, our group described a decrease in absolute uterine artery blood flow, which also correlated with Doppler uterine artery indices of resistance [6] . 37 a,b Least square means with different letter superscripts depict differences at P , 0.05. 
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In contrast to the dietary melatonin supplementation experiment, the current study allowed us to deliver melatonin directly to the fetal vasculature, as evident by the 25% increase in maternal melatonin concentrations versus the 125% increase in umbilical cord melatonin concentrations. The amplitude of melatonin secretion has been associated with improved oxidative status and altered steroid and prostaglandin metabolism in rats and sheep, as well as altered cardiovascular function [21] [22] [23] . Melatonin influences the cardiovascular system by mediating blood pressure [24] , myocardial contractility [25] , and vessel-specific modulation in vascular reactivity [11] . Melatonin receptors 1 and 2 have been described throughout the cardiovascular system, and several pathways have been proposed regarding the vasoconstriction versus vasodilation properties of melatonin. Melatonin receptor activation can lead to a decrease in cAMP levels [26] and stimulate phosphatidylinositol-4,5-bisphosphate hydrolysis [27] . Therefore, melatonin receptor activation on vascular smooth muscle cells is expected to diminish vasodilation by decreasing cAMP or to enhance vasoconstriction by increasing intracellular calcium [11] . Similarly, melatonin receptor activation on endothelial cells leads to an increase in cytosolic calcium; however, this endothelial-specific response activates endothelial nitric oxide synthase, leading to increased vasodilation [11] .
The differential effects of melatonin on vascular blood distribution have been recently examined by Cook et al. [28] , in a study where human subjects showed a significant decrease in renal blood flow, an increase in forearm blood flow, and no change in cerebral blood flow following melatonin ingestion. Similar vascular blood-distribution models have been observed in other species whereby melatonin causes vasodilation of the rat and rabbit aorta, and iliac, renal, and basilar arteries [12, 13] while contracting rat cerebral arteries [26, 29] . Some of these responses have been determined to be melatonin receptor dependent. For example, melatonin incubation enhanced the relaxant response of rat pulmonary arteries to acetylcholine but is abolished with luzindole pretreatment [30] . This differential regulation of arterial vasoconstriction and vasodilation may allow for a circadian rhythmic modification to whole-body blood distribution; however, this hypothesis goes beyond the scope of the current project. It is still interesting to note that melatonin, as a chronobiotic regulator and antioxidant, may indeed influence cardiovascular function in the adult [31] . Fewer studies have examined fetal cardiovascular responses to melatonin or melatonin receptor antagonist treatment. In late gestation, the addition of physiological melatonin concentrations prevented the vasoconstriction caused by norepinephrine in fetal sheep cerebral arteries [32] ; however, treatment with luzindole did not abolish this response [32] . These direct inhibitory responses to melatonin in fetal sheep support a role for melatonin in preventing major contraction of cerebral arteries, decreased lipolysis in brown adipose tissue, and decreased cortisol release [32] .
Independent of melatonergic receptor-specific pathways, melatonin may increase vascular relaxation through its antioxidant properties, whereby increased scavenging of superoxide free radicals may increase the bioavailability of nitric oxide [23, 33] . It is important to note that both melatonin receptor-dependent and -independent pathways are mediated via an increase in nitric oxide production or a decrease in nitric oxide sequestration [11] . Acute melatonin infusion in fetal sheep during late gestation increased umbilical blood flow by approximately 20% [34] . These responses are also in agreement with our own dietary melatonin-supplementation model, which caused a 20% increase in umbilical artery blood flow and no change in uterine artery blood flow [6] . In addition to the physiological increase in blood flow, Thakor et al. [34] imposed a nitric oxide clamp during melatonin infusion, which confirmed that these responses were mediated via nitric oxide production and/or bioavailability. These experiments helped solidify the hypothesis that melatonin supplementation mediates improved placental vascular perfusion via nitric oxidedependent mechanisms. Moreover, Richter et al. [35] reported a concomitant increase in placental Mn-SOD protein expression and rescued birth weight in pregnant rats supplemented with dietary melatonin during a compromised pregnancy. In the current study, we report an increase in caruncular (maternal placenta) SOD activity in sheep chronically infused with melatonin during midgestation, which may partially potentiate the increase in placental blood perfusion. Regardless, this increase in placental antioxidant enzyme activity does not 
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explain the decrease in average umbilical artery blood flow and fetal aorta blood flow in LUZ-infused animals. Similar to the rodent study, we observed an increase in placental efficiency (fetal-placentome weight ratio); however, this effect was only apparent when comparing MEL-infused and LUZ-infused dams. Chronic melatonin infusion decreased caruncle weight compared to control dams. This result may be due to an inhibition of cellular proliferation by melatonin, which has been shown in several cell lines at both physiological and pharmacological concentrations [36] . Unexpectedly, luzindole infusion also decreased caruncle weight compared to control dams, and this may be related to the continuous infusion versus acute and/or daily administration. For example, the antiproliferative effects of melatonin on the MCF-7 cell line were different based on treating cells with chronic versus 12-h diurnal rhythms of melatonin [37] . Moreover, we did not observe any changes in placentome weight, caruncle weight, or cotyledon weight after treating dams with 5 mg/day of dietary melatonin from Day 50 to Day 130 of gestation. Therefore, this decrease in tissue mass may be dependent on local and/or chronic infusion of melatonin and/or melatonin receptor antagonist. In contrast to our previous report, chronic infusion of melatonin or luzindole tended to alter the maternal portion of the placenta, as evident by the decrease in caruncle weight, the increase in total nitrites in the caruncle, and the increase in caruncle SOD activity. These variables were all similar in the fetal portion of the placenta. Recent observations in our laboratory examined the vascular reactivity of caruncular and cotyledonary arteries following maternal dietary melatonin supplementation from Day 50 to Day 130 of gestation. Interestingly, maternal melatonin supplementation increased cotyledonary artery sensitivity to the bradykinin-induced relaxation, with no effect in the caruncular arteries (unpublished observations). Although we are currently examining the potential mechanisms behind melatonin supplementation leading to the increased sensitivity of cotyledonary arteries to bradykinin, a portion of these responses may be melatonergic receptor dependent. It is important to note that daily dietary melatonin supplementation to the dam alters placental responses (e.g., mass, efficiency) differently from the current chronic melatonin infusion study.
